Skip to main content

Table 3 Results of responsiveness testing for FACT-8D and EQ-5D-5L using data from baseline to 31 weeks

From: Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

 FACT-8DEQ-5D-5L CrosswalkEQ-5D-5L EVS
Mean changePESMean changePESMean changePES
FACT-Lym Total (6.5 point MID) [23] < 0.0001  <.0001  <.0001 
 Improve (N = 51) a0.17 0.940.10 0.660.09 0.64
 No change (N = 36)0.01  −0.01  −0.01  
 Worsen (N = 33)−0.121 0.67−0.11 0.73−0.11 0.79
LymS
(5 point MID) [24]
 < 0.0001  <.0001  <.0001 
 Improve (N = 46)0.16 0.760.12 0.750.10 0.67
 No change (N = 58)−0.0002  −0.04  −0.04  
 Worsen (N = 16)−0.16 0.76−0.12 0.75−0.12 0.8
ECOG status 0.63 0.19 0.14
 Improve (N = 26)0.03  0.02  0.00  
 No change (N = 82)0.05  −0.02  0.02  
 Worsen (N = 13)−0.01  −0.07  −0.08  
HgB, </> 120 (women) or 130 g/L (men) [22] 0.002  0.02  0.005 
 Improve (N = 15)0.18 0.860.13 0.760.12 0.75
 No change (N = 76)0.05  0.01  0.00  
 Worsen (N = 30)−0.05 0.24−0.03 0.18−0.04 0.25
  1. ECOG Eastern Cooperative Oncology Group, ES Effect size, EVS England value set, HgB Haemoglobin, LymS FACT-Lym lymphoma specific additional concerns subscale. aThe number of patients showing improvement/worsening/no change corresponds to the total number of patients still in the trial at Week 31 with available changes from baseline on each of the characteristics analysed